Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03224533 · ClinicalTrials.gov registry record
Walnut Consumption and Diabetes Risk
A clinical trial, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 34,121
- Enrollment target
NCT03224533: Completed study, sponsored by University of California, Los Angeles.
NCT03224533 is a clinical trial that has completed, run by University of California, Los Angeles. The registered enrollment target is 34,121 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03224533 has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 34,121 participants
- Enrollment target
Study Summary
Multiple NHANES surveys were combined and weighted to evaluate relationships between walnut consumption and type 2 diabetes mellitus using various independent measures of diabetes status and risk. After risks were ascertained, interactions with gender were analyzed.
Primary Outcome
Based on self-report as told by a doctor
Interventions
- DIAGNOSTIC_TEST Diabetes Outcome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34,121 participants |
| Start Date | 2015-06-01 |
| Est. Completion | 2017-05-30 |
What the finished NCT03224533 record still lists
NCT03224533 is an observational study that tracks outcomes without assigning an intervention. Its 34,121 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Diabetes Outcome is the first listed.
NCT03224533 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03224533 about?
NCT03224533 is a clinical study titled "Walnut Consumption and Diabetes Risk". Multiple NHANES surveys were combined and weighted to evaluate relationships between walnut consumption and type 2 diabetes mellitus using various independent measures of diabetes status and risk. After risks were ascertained, interactions with gender were analyzed.
What is the current status of trial NCT03224533?
This trial is currently completed. The enrollment target is 34,121 participants. The study started on 2015-06-01. Estimated completion is 2017-05-30.
What interventions are being tested in trial NCT03224533?
The interventions under investigation include: Diabetes Outcome (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03224533?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03720613 · 34,532 participants
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
- NCT02225301 · 35,000 participants · NA
iLookOut for Child Abuse -Online Learning Module for Early Childcare Providers
- NCT06145724 · 33,183 participants · NA
EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis (Aim 1)
- NCT04477928 · 33,000 participants
General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI